{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T07:47:04Z","timestamp":1772696824108,"version":"3.50.1"},"reference-count":71,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004697","name":"Hamadan University of Medical Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004697","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pathology - Research and Practice"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1016\/j.prp.2021.153396","type":"journal-article","created":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T01:58:35Z","timestamp":1614563915000},"page":"153396","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"special_numbering":"C","title":["The clinical significance of histone deacetylase-8 in human breast cancer"],"prefix":"10.1016","volume":"220","author":[{"given":"Golebagh","family":"Rahmani","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saba","family":"Sameri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5155-7851","authenticated-orcid":false,"given":"Nooshin","family":"Abbasi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammad","family":"Abdi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1326-1288","authenticated-orcid":false,"given":"Rezvan","family":"Najafi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.prp.2021.153396_bib0005","first-page":"7","article-title":"Cancer statistics, 2016","volume":"66","author":"Siegel","year":"2016","journal-title":"CA: Cancer J. Clin."},{"issue":"6","key":"10.1016\/j.prp.2021.153396_bib0010","doi-asserted-by":"crossref","first-page":"e290","DOI":"10.1016\/S1470-2045(18)30344-9","article-title":"Low uptake of tamoxifen to prevent breast cancer","volume":"19","author":"Gourd","year":"2018","journal-title":"Lancet Oncol."},{"issue":"1","key":"10.1016\/j.prp.2021.153396_bib0015","doi-asserted-by":"crossref","first-page":"35","DOI":"10.21873\/anticanres.11286","article-title":"Histone deacetylase inhibitors: an attractive therapeutic strategy against breast cancer","volume":"37","author":"Damaskos","year":"2017","journal-title":"Anticancer Res."},{"issue":"1","key":"10.1016\/j.prp.2021.153396_bib0020","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/bcr1855","article-title":"Brca1 breast tumors contain distinct CD44+\/CD24-and CD133+ cells with cancer stem cell characteristics","volume":"10","author":"Wright","year":"2008","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.prp.2021.153396_bib0025","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.yexmp.2019.05.001","article-title":"High GD2 expression defines breast cancer cells with enhanced invasiveness","volume":"109","author":"Mansoori","year":"2019","journal-title":"Exp. Mol. Pathol."},{"issue":"9","key":"10.1016\/j.prp.2021.153396_bib0030","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a019505","article-title":"Epigenetic determinants of cancer","volume":"8","author":"Baylin","year":"2016","journal-title":"Cold Spring Harb. Perspect. Biol."},{"issue":"40","key":"10.1016\/j.prp.2021.153396_bib0035","doi-asserted-by":"crossref","first-page":"17678","DOI":"10.1002\/ange.202001205","article-title":"Identification of histone deacetylase (HDAC)\u2010associated proteins with DNA\u2010programmed affinity labeling","volume":"132","author":"Zhang","year":"2020","journal-title":"Angew. Chem."},{"issue":"1","key":"10.1016\/j.prp.2021.153396_bib0040","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1007\/s11427-016-0300-y","article-title":"Exploiting histone deacetylases for cancer therapy: from hematological malignancies to solid tumors","volume":"60","author":"Huang","year":"2017","journal-title":"Sci. China Life Sci."},{"key":"10.1016\/j.prp.2021.153396_bib0045","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.pharmthera.2014.11.006","article-title":"Epigenetic targets for novel therapies of lung diseases","volume":"147","author":"Comer","year":"2015","journal-title":"Pharmacol. Ther."},{"issue":"2","key":"10.1016\/j.prp.2021.153396_bib0050","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1111\/hepr.12757","article-title":"Histone deacetylases function as novel potential therapeutic targets for cancer","volume":"47","author":"Zhang","year":"2017","journal-title":"Hepatol. Res."},{"issue":"3","key":"10.1016\/j.prp.2021.153396_bib0055","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.21873\/anticanres.13220","article-title":"Histone deacetylase inhibitors and anaplastic thyroid carcinoma","volume":"39","author":"Spartalis","year":"2019","journal-title":"Anticancer Res."},{"key":"10.1016\/j.prp.2021.153396_bib0060","article-title":"Histone deacetylases and histone deacetylase inhibitors: molecular mechanisms of action in various cancers","volume":"8","author":"Sanaei","year":"2019","journal-title":"Adv. Biomed. Res."},{"issue":"3","key":"10.1016\/j.prp.2021.153396_bib0065","doi-asserted-by":"crossref","first-page":"780","DOI":"10.3390\/cells9030780","article-title":"Role of histone deacetylases in carcinogenesis: potential role in cholangiocarcinoma","volume":"9","author":"Pant","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.prp.2021.153396_bib0070","first-page":"1","article-title":"A short guide to histone deacetylases including recent progress on class II enzymes","author":"Park","year":"2020","journal-title":"Exp. Mol. Med."},{"issue":"1","key":"10.1016\/j.prp.2021.153396_bib0075","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.canlet.2008.08.016","article-title":"HDAC family: what are the cancer relevant targets?","volume":"277","author":"Witt","year":"2009","journal-title":"Cancer Lett."},{"issue":"7","key":"10.1016\/j.prp.2021.153396_bib0080","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1038\/modpathol.2015.34","article-title":"Expression of the class 1 histone deacetylases HDAC8 and 3 are associated with improved survival of patients with metastatic melanoma","volume":"28","author":"Wilmott","year":"2015","journal-title":"Mod. Pathol."},{"issue":"7","key":"10.1016\/j.prp.2021.153396_bib0085","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.tips.2015.04.013","article-title":"HDAC8: a multifaceted target for therapeutic interventions","volume":"36","author":"Chakrabarti","year":"2015","journal-title":"Trends Pharmacol. Sci."},{"issue":"4","key":"10.1016\/j.prp.2021.153396_bib0090","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a018713","article-title":"Erasers of histone acetylation: the histone deacetylase enzymes","volume":"6","author":"Seto","year":"2014","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"10.1016\/j.prp.2021.153396_bib0095","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1016\/j.biopha.2017.11.065","article-title":"HDACis (class I), cancer stem cell, and phytochemicals: cancer therapy and prevention implications","volume":"97","author":"Bayat","year":"2018","journal-title":"Biomed. Pharmacother."},{"issue":"1","key":"10.1016\/j.prp.2021.153396_bib0100","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/icb.2011.100","article-title":"HDAC inhibitors in cancer biology: emerging mechanisms and clinical applications","volume":"90","author":"Khan","year":"2012","journal-title":"Immunol. Cell Biol."},{"issue":"1","key":"10.1016\/j.prp.2021.153396_bib0105","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13046-019-1448-9","article-title":"NOS1 inhibits the interferon response of cancer cells by S-nitrosylation of HDAC2","volume":"38","author":"Xu","year":"2019","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"4","key":"10.1016\/j.prp.2021.153396_bib0110","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1158\/1535-7163.MCT-08-0985","article-title":"HDAC2 regulates chromatin plasticity and enhances DNA vulnerability","volume":"8","author":"Marchion","year":"2009","journal-title":"Mol. Cancer Ther."},{"issue":"2","key":"10.1016\/j.prp.2021.153396_bib0115","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41368-019-0053-2","article-title":"Harnessing the HDAC\u2013histone deacetylase enzymes, inhibitors and how these can be utilised in tissue engineering","volume":"11","author":"Lawlor","year":"2019","journal-title":"Int. J. Oral Sci."},{"issue":"9","key":"10.1016\/j.prp.2021.153396_bib0120","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1038\/nsmb.1899","article-title":"Human HDAC1 and HDAC2 function in the DNA-damage response to promote DNA nonhomologous end-joining","volume":"17","author":"Miller","year":"2010","journal-title":"Nat. Struct. Mol. Biol."},{"issue":"6","key":"10.1016\/j.prp.2021.153396_bib0125","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1515\/hsz-2017-0306","article-title":"HDAC1 knockdown inhibits invasion and induces apoptosis in non-small cell lung cancer cells","volume":"399","author":"Zhang","year":"2018","journal-title":"Biol. Chem."},{"key":"10.1016\/j.prp.2021.153396_bib0130","doi-asserted-by":"crossref","DOI":"10.1016\/j.mcp.2020.101649","article-title":"MiR-646 prevents proliferation and progression of human breast cancer cell lines by suppressing HDAC2 expression","volume":"53","author":"Darvishi","year":"2020","journal-title":"Mol. Cell. Probes"},{"issue":"2","key":"10.1016\/j.prp.2021.153396_bib0135","first-page":"663","article-title":"Histone deacetylase 3 inhibits new tumor suppressor gene DTWD1 in gastric cancer","volume":"5","author":"Ma","year":"2015","journal-title":"Am. J. Cancer Res."},{"issue":"1","key":"10.1016\/j.prp.2021.153396_bib0140","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s12943-019-1127-7","article-title":"Role of HDACs in normal and malignant hematopoiesis","volume":"19","author":"Wang","year":"2020","journal-title":"Mol. Cancer"},{"issue":"2","key":"10.1016\/j.prp.2021.153396_bib0145","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s10059-010-0094-z","article-title":"Inhibition of histone deacetylase 10 induces thioredoxin-interacting protein and causes accumulation of reactive oxygen species in SNU-620 human gastric cancer cells","volume":"30","author":"Lee","year":"2010","journal-title":"Mol. Cells"},{"issue":"5","key":"10.1016\/j.prp.2021.153396_bib0150","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.cellsig.2016.02.006","article-title":"Histone deacetylase inhibitors suppress mutant p53 transcription via HDAC8\/YY1 signals in triple negative breast cancer cells","volume":"28","author":"Wang","year":"2016","journal-title":"Cell. Signal."},{"issue":"25","key":"10.1016\/j.prp.2021.153396_bib0155","doi-asserted-by":"crossref","first-page":"37966","DOI":"10.18632\/oncotarget.9274","article-title":"HDAC5, a potential therapeutic target and prognostic biomarker, promotes proliferation, invasion and migration in human breast cancer","volume":"7","author":"Li","year":"2016","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.prp.2021.153396_bib0160","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13045-018-0654-9","article-title":"Histone deacetylase 6 in cancer","volume":"11","author":"Li","year":"2018","journal-title":"J. Hematol. Oncol."},{"issue":"1","key":"10.1016\/j.prp.2021.153396_bib0165","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12943-017-0736-2","article-title":"Hdac7 promotes lung tumorigenesis by inhibiting Stat3 activation","volume":"16","author":"Lei","year":"2017","journal-title":"Mol. Cancer"},{"issue":"4","key":"10.1016\/j.prp.2021.153396_bib0170","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1111\/jop.12560","article-title":"Histone deacetylase 7 silencing induces apoptosis and autophagy in salivary mucoepidermoid carcinoma cells","volume":"46","author":"Ahn","year":"2017","journal-title":"J. Oral Pathol. Med."},{"key":"10.1016\/j.prp.2021.153396_bib0175","doi-asserted-by":"crossref","first-page":"2177","DOI":"10.2147\/OTT.S164583","article-title":"Overexpression of HDAC9 is associated with poor prognosis and tumor progression of breast cancer in Chinese females","volume":"11","author":"Huang","year":"2018","journal-title":"OncoTargets Ther."},{"issue":"37","key":"10.1016\/j.prp.2021.153396_bib0180","doi-asserted-by":"crossref","first-page":"59388","DOI":"10.18632\/oncotarget.10673","article-title":"HDAC10 promotes lung cancer proliferation via AKT phosphorylation","volume":"7","author":"Yang","year":"2016","journal-title":"Oncotarget"},{"issue":"12","key":"10.1016\/j.prp.2021.153396_bib0185","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.3390\/cancers11121949","article-title":"The roles of sirtuin family proteins in cancer progression","volume":"11","author":"Zhao","year":"2019","journal-title":"Cancers"},{"key":"10.1016\/j.prp.2021.153396_bib0190","doi-asserted-by":"crossref","first-page":"38","DOI":"10.3389\/fphar.2019.00038","article-title":"Dual tumor suppressor and tumor promoter action of sirtuins in determining malignant phenotype","volume":"10","author":"Carafa","year":"2019","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.prp.2021.153396_bib0195","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2020.110607","article-title":"HDAC11: a rising star in epigenetics","volume":"131","author":"Liu","year":"2020","journal-title":"Biomed. Pharmacother."},{"issue":"1","key":"10.1016\/j.prp.2021.153396_bib0200","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-020-61295-6","article-title":"Novel HDAC11 inhibitors suppress lung adenocarcinoma stem cell self-renewal and overcome drug resistance by suppressing Sox2","volume":"10","author":"Bora-Singhal","year":"2020","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.prp.2021.153396_bib0205","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.jmb.2004.02.006","article-title":"Molecular evolution of the histone deacetylase family: functional implications of phylogenetic analysis","volume":"338","author":"Gregoretti","year":"2004","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.prp.2021.153396_bib0210","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.redox.2018.09.013","article-title":"The enzyme activity of histone deacetylase 8 is modulated by a redox-switch","volume":"20","author":"J\u00e4nsch","year":"2019","journal-title":"Redox Biol."},{"issue":"12","key":"10.1016\/j.prp.2021.153396_bib0215","doi-asserted-by":"crossref","first-page":"20092","DOI":"10.18632\/oncotarget.15383","article-title":"HDAC8 functions in spindle assembly during mouse oocyte meiosis","volume":"8","author":"Zhang","year":"2017","journal-title":"Oncotarget"},{"issue":"7","key":"10.1016\/j.prp.2021.153396_bib0220","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1016\/j.str.2004.04.012","article-title":"Structural snapshots of human HDAC8 provide insights into the class I histone deacetylases","volume":"12","author":"Somoza","year":"2004","journal-title":"Structure"},{"issue":"22","key":"10.1016\/j.prp.2021.153396_bib0225","doi-asserted-by":"crossref","first-page":"10000","DOI":"10.1021\/acs.jmedchem.8b01087","article-title":"Characterization of histone deacetylase 8 (HDAC8) selective inhibition reveals specific active site structural and functional determinants","volume":"61","author":"Marek","year":"2018","journal-title":"J. Med. Chem."},{"issue":"13","key":"10.1016\/j.prp.2021.153396_bib0230","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.4155\/fmc-2016-0117","article-title":"Targeting histone deacetylase 8 as a therapeutic approach to cancer and neurodegenerative diseases","volume":"8","author":"Chakrabarti","year":"2016","journal-title":"Future Med. Chem."},{"issue":"4","key":"10.1016\/j.prp.2021.153396_bib0235","first-page":"769","article-title":"Expression profile of class I histone deacetylases in human cancer tissues","volume":"18","author":"Nakagawa","year":"2007","journal-title":"Oncol. Rep."},{"issue":"6","key":"10.1016\/j.prp.2021.153396_bib0240","first-page":"1677","article-title":"Histone deacetylases 1, 6 and 8 are critical for invasion in breast cancer","volume":"25","author":"Park","year":"2011","journal-title":"Oncol. Rep."},{"issue":"1","key":"10.1016\/j.prp.2021.153396_bib0245","first-page":"24","article-title":"An atlas of histone deacetylase expression in breast cancer: fluorescence methodology for comparative semi-quantitative analysis","volume":"4","author":"Ververis","year":"2012","journal-title":"Am. J. Transl. Res."},{"issue":"24","key":"10.1016\/j.prp.2021.153396_bib0250","doi-asserted-by":"crossref","first-page":"12761","DOI":"10.1074\/jbc.M115.704627","article-title":"HDAC8 inhibition blocks SMC3 deacetylation and delays cell cycle progression without affecting cohesin-dependent transcription in MCF7 cancer cells","volume":"291","author":"Dasgupta","year":"2016","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.prp.2021.153396_bib0255","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.lfs.2016.02.092","article-title":"Alterations in histone deacetylase 8 lead to cell migration and poor prognosis in breast cancer","volume":"151","author":"Hsieh","year":"2016","journal-title":"Life Sci."},{"key":"10.1016\/j.prp.2021.153396_bib0260","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.ejphar.2018.12.030","article-title":"Histone deacetylase 8 triggers the migration of triple negative breast cancer cells via regulation of YAP signals","volume":"845","author":"An","year":"2019","journal-title":"Eur. J. Pharmacol."},{"issue":"5","key":"10.1016\/j.prp.2021.153396_bib0265","doi-asserted-by":"crossref","first-page":"283","DOI":"10.29252\/ibj.24.5.283","article-title":"Association of HDAC8 expression with pathological findings in triple negative and non-triple negative breast cancer: implications for diagnosis","volume":"24","author":"Menbari","year":"2020","journal-title":"Iran. Biomed. J."},{"issue":"3","key":"10.1016\/j.prp.2021.153396_bib0270","doi-asserted-by":"crossref","first-page":"2631","DOI":"10.1002\/jcp.29167","article-title":"miR\u2010483\u20103p suppresses the proliferation and progression of human triple negative breast cancer cells by targeting the HDAC8& oncogene","volume":"235","author":"Menbari","year":"2020","journal-title":"J. Cell. Physiol."},{"key":"10.1016\/j.prp.2021.153396_bib0275","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2019.116945","article-title":"MiR-216b-5p inhibits cell proliferation in human breast cancer by down-regulating HDAC8 expression","volume":"237","author":"Menbari","year":"2019","journal-title":"Life Sci."},{"key":"10.1016\/j.prp.2021.153396_bib0280","first-page":"1","article-title":"HDAC8 promotes the dissemination of breast cancer cells via AKT\/GSK-3\u03b2\/Snail signals","author":"An","year":"2020","journal-title":"Oncogene"},{"issue":"6","key":"10.1016\/j.prp.2021.153396_bib0285","doi-asserted-by":"crossref","first-page":"2912","DOI":"10.1093\/nar\/gkaa039","article-title":"HDAC8 cooperates with SMAD3\/4 complex to suppress SIRT7 and promote cell survival and migration","volume":"48","author":"Tang","year":"2020","journal-title":"Nucleic Acids Res."},{"issue":"1","key":"10.1016\/j.prp.2021.153396_bib0290","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-017-17006-9","article-title":"Addition of a histone deacetylase inhibitor increases recombinant protein expression in Medicago truncatula cell cultures","volume":"7","author":"Santos","year":"2017","journal-title":"Sci. Rep."},{"issue":"6","key":"10.1016\/j.prp.2021.153396_bib0295","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.3390\/cancers12061664","article-title":"Roles of histone deacetylases and inhibitors in anticancer therapy","volume":"12","author":"Verza","year":"2020","journal-title":"Cancers"},{"issue":"10","key":"10.1016\/j.prp.2021.153396_bib0300","doi-asserted-by":"crossref","first-page":"5019","DOI":"10.21873\/anticanres.11070","article-title":"Histone deacetylase inhibitors: a novel therapeutic weapon against medullary thyroid cancer?","volume":"36","author":"Damaskos","year":"2016","journal-title":"Anticancer Res."},{"issue":"4","key":"10.1016\/j.prp.2021.153396_bib0305","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.det.2015.05.010","article-title":"Histone deacetylase inhibitors for cutaneous T-cell lymphoma","volume":"33","author":"Duvic","year":"2015","journal-title":"Dermatol. Clin."},{"issue":"3","key":"10.1016\/j.prp.2021.153396_bib0310","first-page":"4170","article-title":"Inhibition of mouse B16 melanoma by sodium butyrate correlated to tumor associated macrophages differentiation suppression","volume":"8","author":"Xiong","year":"2015","journal-title":"Int. J. Clin. Exp. Med."},{"issue":"Sup 3","key":"10.1016\/j.prp.2021.153396_bib0315","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1080\/14756366.2016.1210138","article-title":"N-(2-Hydroxyphenyl)-2-propylpentanamide, a valproic acid aryl derivative designed in silico with improved anti-proliferative activity in HeLa, rhabdomyosarcoma and breast cancer cells","volume":"31","author":"Prestegui-Martel","year":"2016","journal-title":"J. Enzyme Inhib. Med. Chem."},{"issue":"5","key":"10.1016\/j.prp.2021.153396_bib0320","first-page":"299","article-title":"Histone deacetylases as new therapeutic targets in triple-negative breast cancer: progress and promises","volume":"14","author":"Garmpis","year":"2017","journal-title":"Cancer Genom.-Proteom."},{"issue":"11","key":"10.1016\/j.prp.2021.153396_bib0325","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1042\/CS20120504","article-title":"Histone deacetylases as targets for treatment of multiple diseases","volume":"124","author":"Tang","year":"2013","journal-title":"Clin. Sci."},{"issue":"8","key":"10.1016\/j.prp.2021.153396_bib0330","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1002\/ijc.22474","article-title":"Multiple histone deacetylases repress tumor suppressor gene ARHI in breast cancer","volume":"120","author":"Feng","year":"2007","journal-title":"Int. J. Cancer"},{"issue":"1","key":"10.1016\/j.prp.2021.153396_bib0335","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1515\/hsz-2015-0215","article-title":"Suberoylanilide hydroxamic acid (SAHA) promotes the epithelial mesenchymal transition of triple negative breast cancer cells via HDAC8\/FOXA1 signals","volume":"397","author":"Wu","year":"2016","journal-title":"Biol. Chem."},{"issue":"6","key":"10.1016\/j.prp.2021.153396_bib0340","doi-asserted-by":"crossref","first-page":"4525","DOI":"10.3892\/mmr.2015.3268","article-title":"Trichostatin A, a histone deacetylase inhibitor, suppresses proliferation and promotes apoptosis of esophageal squamous cell lines","volume":"11","author":"Ma","year":"2015","journal-title":"Mol. Med. Rep."},{"issue":"1","key":"10.1016\/j.prp.2021.153396_bib0345","first-page":"10","article-title":"The histone deacetylase inhibitor trichostatin A alters microRNA expression profiles in apoptosis-resistant breast cancer cells","volume":"27","author":"Rhodes","year":"2012","journal-title":"Oncol. Rep."},{"issue":"1","key":"10.1016\/j.prp.2021.153396_bib0350","first-page":"435","article-title":"Histone deacetylase inhibitors alter the expression of molecular markers in breast cancer cells via microRNAs","volume":"42","author":"Shi","year":"2018","journal-title":"Int. J. Mol. Med."},{"issue":"11","key":"10.1016\/j.prp.2021.153396_bib0355","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1007\/s10495-017-1410-2","article-title":"Novel histone deacetylase 8-selective inhibitor 1, 3, 4-oxadiazole-alanine hybrid induces apoptosis in breast cancer cells","volume":"22","author":"Pidugu","year":"2017","journal-title":"Apoptosis"}],"container-title":["Pathology - Research and Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0344033821000571?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0344033821000571?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T06:45:34Z","timestamp":1759733134000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0344033821000571"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":71,"alternative-id":["S0344033821000571"],"URL":"https:\/\/doi.org\/10.1016\/j.prp.2021.153396","relation":{},"ISSN":["0344-0338"],"issn-type":[{"value":"0344-0338","type":"print"}],"subject":[],"published":{"date-parts":[[2021,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The clinical significance of histone deacetylase-8 in human breast cancer","name":"articletitle","label":"Article Title"},{"value":"Pathology - Research and Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.prp.2021.153396","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier GmbH. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"153396"}}